CEVR Leaders Publish NEJM Article on Determining Value Using Cost-Effectiveness Analyses

Peter Neumann, Sc.D., Joshua Cohen, Ph.D., and Daniel Ollendorf, Ph.D. of the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center recently published an article in the New England Journal of Medicine (NEJM) on using cost-effectiveness analyses to determine a drug’s price.

“The idea of permitting the government to negotiate pharmaceutical prices raises a question about the basis for negotiations: how to judge what’s a fair price. Absent well-functioning markets, cost-effectiveness analyses can clarify the value that therapies deliver.” Read more here.

(Source: Neumann et al., NEJM, 11/13/21)